Articles by tag: rare-blood-cancer

ADC drug Decnupaz: treatment of ultra-rare blood cancer BPDCN

FDA approved pivekimab sunirin (Decnupaz) for BPDCN with complete remission of 69.7%. Analysis of efficacy, risks, price, and prospects in AML. Read more.

Targeted therapy for ultra-rare blood cancer: FDA approves pivekimab sunirin

FDA has registered the first targeted therapy for BPDCN — pivekimab sunirin. Remission rate 69.7%, but there are risks. Detailed analysis of the drug and consequences.